Camps Herrero, C. http://orcid.org/0000-0002-0648-5403
Batista, N.
Díaz Fernández, N.
Escobar Álvarez, Y.
Gonzalo Gómez, A.
Isla Casado, D.
Salud, A.
Terrasa Pons, J.
Guillem Porta, V.
Article History
Received: 23 October 2019
Accepted: 8 December 2019
First Online: 30 January 2020
Compliance with ethical standards
:
: The authors state that they have no conflicts of interest. <i>Camps C</i>. has received speaker honoraria from AstraZeneca, Roche, MSD, Pfizer, Bristol-Myers Squibb. He is an advisory board member at AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Roche, Bayer and Angellini. He has received research funding from AstraZeneca and Bristol-Myers Squibb. <i>Ilsa D.</i> has received speaker honoraria from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche, MSD, Novartis, Pierre Fabre and Pfizer, and consultation honoraria from AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche, Merck, MSD, Novartis, Pierre Fabre, Pfizer and Takeda. She has received research funding from AstraZeneca, BMS, F. Hoffmann-La Roche, MSD and Pierre Fabre. Additionally, she has a leadership role as an Executive Board Member of the Commission for the Approval of New Drugs. Regional Health Care Department, Spain.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: For this type of study, formal consent is not required.